Combined Diffusion and Perfusion MR Imaging as Biomarkers of Prognosis in Immunocompetent Patients with Primary Central Nervous System Lymphoma

References

1. 1.↵
   1. Deckert M,
   2. Engert A,
   3. Bruck W,
   4. et al

   . Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. Leukemia 2011;25:1797–807

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Olson JE,
   2. Janney CA,
   3. Rao RD,
   4. et al

   . The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer 2002;95:1504–10

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Eby NL,
   2. Grufferman S,
   3. Flannelly CM,
   4. et al

   . Increasing incidence of primary brain lymphoma in the US. Cancer 1988;62:2461–65

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Schlegel U,
   2. Schmidt-Wolf IG,
   3. Deckert M

   . Primary CNS lymphoma: Clinical presentation, pathological classification, molecular pathogenesis and treatment. J Neurol Sci 2000;181:1–12

   CrossRefPubMed
5. 5.↵
   1. Hochberg FB,
   2. Hochberg E

   . Primary CNS lymphoma. Nat Clin Pract Neurol 2007;3:24–35

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Wolf T,
   2. Brodt HR,
   3. Fichtlscherer S,
   4. et al

   . Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma 2005;46:207–15

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Bayraktar S,
   2. Bayraktar UD,
   3. Ramos JC,
   4. et al

   . Primary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors. J Neurooncol 2011;101:257–65

   CrossRefPubMed
8. 8.↵
   1. Abrey LE,
   2. Batchelor TT,
   3. Ferreri AJ,
   4. et al.

   , for the International Primary CNS Lymphoma Collaborative Group. Report on an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005;23:5034–43

   Abstract/FREE Full Text
9. 9.↵
   1. Ferreri AJ,
   2. Blay JY,
   3. Reni M,
   4. et al

   . Prognostic scoring system for primary CNS lymphomas: the international extranodal lymphoma study group experience. J Clin Oncol 2003;21:266–72

   Abstract/FREE Full Text
10. 10.↵
    1. Mathew BS,
    2. Carson KA,
    3. Grossman SA

    . Initial response to glucocorticoids. Cancer 2006;106:383–87

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Cha S

    . Update on brain tumor imaging: from anatomy to physiology. AJNR Am J Neuroradiol 2006;27:475–87

    FREE Full Text
12. 12.↵
    1. Barajas RF Jr.,
    2. Rubenstein JL,
    3. Chang JS,
    4. et al

    . Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma. AJNR Am J Neuroradiol 2009;31:60–66

    PubMed
13. 13.↵
    1. Hirai T,
    2. Murakami R,
    3. Nakamura H,
    4. et al

    . Prognostic value of perfusion MR imaging of high-grade astrocytomas: Long-term follow-up study. AJNR Am J Neuroradiol 2008;29:1505–10

    Abstract/FREE Full Text
14. 14.↵
    1. Whitmore RG,
    2. Krejza J,
    3. Kapoor GS,
    4. et al

    . Prediction of oligodendroglial tumor subtype and grade using perfusion weighted magnetic resonance imaging. J Neurosurg 2007;107:600–09

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Chaskis C,
    2. Stadnik T,
    3. Michotte A,
    4. et al

    . Prognostic value of perfusion-weighted imaging in brain glioma: a prospective study. Acta Neurochir (Wien). 2006;148:277–85, discussion 285

    CrossRefPubMed
16. 16.↵
    1. Caseiras GB,
    2. Chheang S,
    3. Babb J,
    4. et al

    . Relative cerebral blood volume measurements of low-grade gliomas predict patient outcome in a multi-institution setting. Eur J Radiol 2010;73:215–20

    CrossRefPubMed
17. 17.↵
    1. Cha S,
    2. Lupo JM,
    3. Chen MH,
    4. et al

    . Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol 2007;28:1078–84

    Abstract/FREE Full Text
18. 18.↵
    1. Guo AC,
    2. Cummings TJ,
    3. Dash RC,
    4. et al

    . Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. Radiology 2002;224:177–83

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Herneth AM,
    2. Guccione S,
    3. Bednarski M

    . Apparent diffusion coefficient: a quantitative parameter for in vivo tumor characterization. Eur J Radiol 2003;45:208–13

    CrossRefPubMed
20. 20.↵
    1. Khayal IS,
    2. Vandenberg SR,
    3. Smith KJ,
    4. et al

    . MRI apparent diffusion coefficient reflects histopathologic subtype, axonal disruption, and tumor fraction in diffuse-type grade II gliomas. Neuro Oncol 2011;13:1192–201

    Abstract/FREE Full Text
21. 21.↵
    1. Sugahara T,
    2. Korogi Y,
    3. Kochi M,
    4. et al

    . Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 1999;9:53–60

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Kim JA,
    2. Kim SJ,
    3. Do IG,
    4. et al

    . Hypoxia-associated protein expression in primary central nervous system diffuse large b-cell lymphoma: does it predict prognosis? Leuk Lymphoma 2011;52:205–13

    CrossRefPubMedWeb of Science
23. 23.↵
    1. Amberger-Murphy V

    . Hypoxia helps glioma to fight therapy. Curr Cancer Drug Targets 2009;9:381–90

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Yetkin FZ,
    2. Mendelsohn D

    . Hypoxia imaging in brain tumors. Neuroimaging Clin N Am 2002;12:537–52

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Knisely JP,
    2. Rockwell S

    . Importance of hypoxia in the biology and treatment of brain tumors. Neuroimaging Clin N Am 2002;12:525–36

    CrossRefPubMedWeb of Science
26. 26.↵
    1. Rubenstein JL,
    2. Fridlyand J,
    3. Abrey L,
    4. et al

    . Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 2007;25:1350–56

    Abstract/FREE Full Text
27. 27.↵
    1. Soussain C,
    2. Hoang-Xuan K,
    3. Taillandier L,
    4. et al

    . Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol 2008;26:2512–18

    Abstract/FREE Full Text
28. 28.↵
    1. Matsumoto Y,
    2. Horiike S,
    3. Fujimoto Y,
    4. et al

    . Effectiveness and limitation of gamma knife radiosurgery for relapsed central nervous system lymphoma: a retrospective analysis in one institution. Int J Hematol 2007;85:333–37

    CrossRefPubMed
29. 29.↵
    1. Ryken TC,
    2. Meeks SL,
    3. Pennington EC,
    4. et al

    . Initial clinical experience with frameless stereotactic radiosurgery: analysis of accuracy and feasibility. Int J Radiat Oncol Biol Phys 2001;51:1152–58

    PubMed